Us aid cuts halt hiv vaccine research in south africa, with global impact
South Africa has been hit especially hard because of Trump's baseless claims about the targeting of the country's white Afrikaner minority. The country had been receiving about 400 million a year via USAID and the HIV-focused PEPFAR. Now that's gone. Glenda Grey, who heads the Brilliant program, said the African continent has been vital to the development of HIV medication, and the US cuts threaten its capability to do such work in the future. Significant advances have included clinical trials for lenacapavir, the world's only twice-a-year shot to prevent HIV, recently approved for use by the US Food and Drug Administration. One study to show its efficacy involved young South Africans. 'We do the trials better, faster, and cheaper than anywhere else in the world, and so without South Africa as part of these programs, the world in my opinion is much poorer,' Gray said.
She noted that during the urgency of the COVID-19 pandemic, South Africa played a crucial role by testing the Johnson & Johnson and Novavax vaccines, and South African scientists' genomic surveillance led to the identification of an important variant.
A team of researchers at the University of the Witwatersrand has been part of the unit developing the HIV vaccines for the trials. Inside the Wits laboratory, technician Nozipho Mlotshwa was among the young people in white gowns working on samples, but she may soon be out of a job. Her position is grant-funded. She uses her salary to support her family and fund her studies in a country where youth unemployment hovers around 46 percent. 'It's very sad and devastating honestly,' she said of the US cuts and overall uncertainty. 'We'll also miss out collaborating with other scientists across the continent.' Professor Abdullah Ely leads the team of researchers. He said the work had promising results, indicating that the vaccines were producing an immune response. But now that momentum, he said, has all kind of had to come to a halt. The BRILLIANT program is scrambling to find money to save the project. The purchase of key equipment has stopped. South Africa's health department says about 100 researchers for that program and others related to HIV have been laid off. Funding for postdoctoral students involved in experiments for the projects is at risk.
South Africa's government has estimated that universities and science councils could lose about 107 million in US research funding over the next five years due to the aid cuts, which affect not only work on HIV but also tuberculosis – another disease with a high number of cases in the country.
Less money and less data on what's affected. South Africa's government has said it will be very difficult to find funding to replace the US support. And now the number of HIV infections will grow. Medication is more difficult to obtain. At least 8,000 health workers in South Africa's HIV program have already been laid off, the government has said. Also gone are the data collectors who tracked patients and their care, as well as HIV counselors who could reach vulnerable patients in rural communities. For researchers, Universities South Africa, an umbrella body, has applied to the national treasury for over 110 million for projects at some of the largest schools.
During a visit to South Africa in June, UNAIDS executive director Winnie Byanyima was well aware of the stakes and the lives at risk as research and health care struggle in South Africa and across Africa at large. Other countries that were highly dependent on US funding, including Zambia, Nigeria, Burundi, and Ivory Coast, are already increasing their own resources, she said. 'But let's be clear, what they are putting down will not be funding in the same way that the American resources were funding,' Byanyima said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Asharq Al-Awsat
20 hours ago
- Asharq Al-Awsat
Trump Says Coca-Cola to Switch to Cane Sugar in US
Beverage giant Coca-Cola has agreed to use real cane sugar in its US production, President Donald Trump announced Wednesday on social media. The company currently uses high-fructose corn syrup (HFCS) in its domestic beverages -- a sweetener that has long drawn criticism from Health Secretary Robert F. Kennedy Jr. and his Make America Healthy Again movement, AFP said. "I have been speaking to Coca-Cola about using REAL Cane Sugar in Coke in the United States, and they have agreed to do so," Trump wrote on his Truth Social platform. "I'd like to thank all of those in authority at Coca-Cola. This will be a very good move by them -- You'll see. It's just better!" The US president did not explain what motivated his push for the change, which would not impact his well-known favorite beverage, Diet Coke. Since his return to the White House, Trump has re-installed a special button in the Oval Office which summons a helping of the sugar-free carbonated drink. Coca-Cola did not immediately confirm the ingredient shift. "We appreciate President Trump's enthusiasm for our iconic Coca‑Cola brand. More details on new innovative offerings within our Coca‑Cola product range will be shared soon," the company said in a short statement. HFCS became popular in the 1970s, with its use skyrocketing thanks to government subsidies for corn growers and high import tariffs on cane sugar. Any shift away from corn is likely to draw backlash in the Corn Belt, a Midwestern region that has been a stronghold of support for Trump. Both HFCS and sucrose (cane sugar) are composed of fructose and glucose. However, they differ structurally: HFCS contains free (unbonded) fructose and glucose in varying ratios -- 55/45 in soft drinks -- while sucrose consists of the two sugars chemically bonded together. These structural differences, however, don't appear to significantly affect health outcomes. A 2022 review of clinical studies found no meaningful differences between HFCS and sucrose in terms of weight gain or heart health. The only notable distinction was an increase in a marker of inflammation in people consuming HFCS. Overall, both sweeteners appear similarly impactful when consumed at equal calorie levels. Despite this, Mexican Coke -- which is made with cane sugar -- is often sold at a premium in US stores and prized for its more "natural" flavor. Trump's prized Diet Coke is sweetened with aspartame -- a compound classified as a "possible carcinogen" by the International Agency for Research on Cancer (IARC).
Al Arabiya
2 days ago
- Al Arabiya
Conservationists Release Rehabilitated Vultures Back Into The Wild On South African Mountain
Five vultures rescued and rehabilitated by a conservation group have been released back into the wild on a mountain range in South Africa. Two of the Cape Vultures were rescued from the illegal wildlife trade where the bird's body parts are sought after for potions and charms. One of them had all its feathers removed, and the Vulpro vulture conservation group looked after it for nearly a year while they grew back. Two of the other vultures were injured in the wild. One was saved after it landed in a dam and became waterlogged and was unable to fly, conservationists said. The birds were set free on the Magaliesburg Mountains in northern South Africa, where there is an existing vulture colony. Vultures generally are not well-loved because of their appearance and because they feed entirely on carrion–or dead animal carcasses–and are often associated with death. But conservationists say these scavengers are critical for cleaning up ecosystems and preventing animal and human disease outbreaks. Because of their eating habits, vultures are also susceptible to mass poisoning when poachers target other animals, and they can die in their hundreds from a poisoned carcass. Six of Africa's other native vulture species are listed as endangered or critically endangered. The Cape Vulture was removed from the endangered list in 2021 after successful conservation efforts but is still classified as vulnerable. The vulture release was organized by Vulpro and the Humane World for Animals organization.
Al Arabiya
5 days ago
- Al Arabiya
Us aid cuts halt hiv vaccine research in south africa, with global impact
Just a week remained before scientists in South Africa were to begin clinical trials of an HIV vaccine, and hopes were high for another step toward limiting one of history's deadliest pandemics. Then the email arrived. 'Stop all work,' it said. The United States, under the Trump administration, was withdrawing all its funding. The news devastated the researchers who live and work in a region where more people live with HIV than anywhere else in the world. Their research project, called BRILLIANT, was meant to be the latest to draw on the region's genetic diversity and deep expertise in the hope of benefiting people everywhere. But the 46 million from the US for the project was disappearing, part of the dismantling of foreign aid by the world's biggest donor earlier this year as President Donald Trump announced a focus on priorities at home. South Africa has been hit especially hard because of Trump's baseless claims about the targeting of the country's white Afrikaner minority. The country had been receiving about 400 million a year via USAID and the HIV-focused PEPFAR. Now that's gone. Glenda Grey, who heads the Brilliant program, said the African continent has been vital to the development of HIV medication, and the US cuts threaten its capability to do such work in the future. Significant advances have included clinical trials for lenacapavir, the world's only twice-a-year shot to prevent HIV, recently approved for use by the US Food and Drug Administration. One study to show its efficacy involved young South Africans. 'We do the trials better, faster, and cheaper than anywhere else in the world, and so without South Africa as part of these programs, the world in my opinion is much poorer,' Gray said. She noted that during the urgency of the COVID-19 pandemic, South Africa played a crucial role by testing the Johnson & Johnson and Novavax vaccines, and South African scientists' genomic surveillance led to the identification of an important variant. A team of researchers at the University of the Witwatersrand has been part of the unit developing the HIV vaccines for the trials. Inside the Wits laboratory, technician Nozipho Mlotshwa was among the young people in white gowns working on samples, but she may soon be out of a job. Her position is grant-funded. She uses her salary to support her family and fund her studies in a country where youth unemployment hovers around 46 percent. 'It's very sad and devastating honestly,' she said of the US cuts and overall uncertainty. 'We'll also miss out collaborating with other scientists across the continent.' Professor Abdullah Ely leads the team of researchers. He said the work had promising results, indicating that the vaccines were producing an immune response. But now that momentum, he said, has all kind of had to come to a halt. The BRILLIANT program is scrambling to find money to save the project. The purchase of key equipment has stopped. South Africa's health department says about 100 researchers for that program and others related to HIV have been laid off. Funding for postdoctoral students involved in experiments for the projects is at risk. South Africa's government has estimated that universities and science councils could lose about 107 million in US research funding over the next five years due to the aid cuts, which affect not only work on HIV but also tuberculosis – another disease with a high number of cases in the country. Less money and less data on what's affected. South Africa's government has said it will be very difficult to find funding to replace the US support. And now the number of HIV infections will grow. Medication is more difficult to obtain. At least 8,000 health workers in South Africa's HIV program have already been laid off, the government has said. Also gone are the data collectors who tracked patients and their care, as well as HIV counselors who could reach vulnerable patients in rural communities. For researchers, Universities South Africa, an umbrella body, has applied to the national treasury for over 110 million for projects at some of the largest schools. During a visit to South Africa in June, UNAIDS executive director Winnie Byanyima was well aware of the stakes and the lives at risk as research and health care struggle in South Africa and across Africa at large. Other countries that were highly dependent on US funding, including Zambia, Nigeria, Burundi, and Ivory Coast, are already increasing their own resources, she said. 'But let's be clear, what they are putting down will not be funding in the same way that the American resources were funding,' Byanyima said.
